Evidence map›Paper›PMID 36426600›Full record

ReviewEpidemiology and psychiatric sciences2022

Clozapine haematological monitoring for neutropenia: a global perspective.

Ebenezer Oloyede, Graham Blackman, Eromona Whiskey, Christian Bachmann, Olubanke Dzahini, Sukhi Shergill, David Taylor, Philip McGuire, James MacCabe

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Epidemiology and psychiatric sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 5 pooled it
9.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 5 syntheses or guidelines pooled it, 65 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Article
  9. Genetic overlap between treatment-resistant schizophrenia and smoking initiation.The international journal of neuropsychopharmacology · 2026
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Review
  19. Polygenic overlap with granulocyte counts identifies novel loci for clozapine metabolism and clozapine-induced agranulocytosis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Ebenezer OloyedePharmacy Department, South London and Maudsley NHS Foundation Trust, London, UK.ORCID https://orcid.org/0000-0003-1352-4017
Graham BlackmanDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Eromona WhiskeyPharmacy Department, South London and Maudsley NHS Foundation Trust, London, UK.
Christian BachmannDepartment of Child and Adolescent Psychiatry, Universitätsklinikum Ulm, Steinhövelstr. 5, 89075, Ulm, Germany.
Olubanke DzahiniPharmacy Department, South London and Maudsley NHS Foundation Trust, London, UK.ORCID https://orcid.org/0000-0003-3878-2143
Sukhi ShergillDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
David TaylorPharmacy Department, South London and Maudsley NHS Foundation Trust, London, UK.
Philip McGuireDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
James MacCabeDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
King's College London · GBSouth London and Maudsley NHS Foundation Trust · GBUniversity Hospital Ulm · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsClozapine is licensed for treatment-resistant psychosis and remains underutilised. This may berelated to the stringent haematological monitoring requirements that are mandatory in most countries. We aimed to compare guidelines internationally and develop a novel Stringency Index. We hypothesised that the most stringent countries would have increased healthcare costs and reduced prescription rates.

methodWe conducted a literature review and survey of guidelines internationally. Guideline identification involved a literature review and consultation with clinical academics. We focused on the haematological monitoring parameters, frequency and thresholds for discontinuation and rechallenge after suspected clozapine-induced neutropenia. In addition, indicators reflecting monitoring guideline stringency were scored and visualised using a choropleth map. We developed a Stringency Index with an international panel of clozapine experts, through a modified-Delphi-survey. The Stringency Index was compared to health expenditure per-capita and clozapine prescription per 100 000 persons.

resultsOne hundred twocountries were included, from Europe (

conclusionsRecommendations on how haematological function should be monitored in patients treated with clozapine vary considerably between countries. It would be useful to standardise guidelines on haematological monitoring worldwide.

Indexed as

Antipsychotic AgentsClozapineNeutropeniaPsychotic DisordersAustraliaHumansAntipsychotic AgentsClozapineAdverse drug reactionnational guidelinessafetystringency indextolerabilitytreatment discontinuationtreatment-resistant schizophrenia

Identifiers

PMID36426600
PMCPMC9714212
OpenAlexW4310641959

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.